Medication info
Pashiga Jeng 10mg (Dapagliflozin Propanediol Hydrate)

Pashiga Jeng 10mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Korea Pavise Pharmaceutical Co., Ltd.
Appearance
Yellow, biconvex, rhomboid film-coated tablets
Packaging
28 tablets/box [14 tablets/Alu-Alu*2]
Approval status
Active

MFDS item code 202301304 · Approved 2023.04.21

Summary

Main use
Treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other blood glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine is not recommended for improving glycemic control. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Korea Pavise Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes, chronic heart failure, and chronic kidney disease

  • Type 2 diabetes
  • blood sugar control disorders
  • cardiovascular diseases
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • reduced estimated glomerular filtration rate
  • end-stage renal disease
View approved original text

This medication is used along with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It also aids in reducing the occurrence of cardiovascular events in patients at risk of cardiovascular diseases. In patients with chronic heart failure, it is used alongside other treatments to lower the risk of death and hospitalization due to cardiovascular diseases. It is also utilized to decrease the risk of kidney function decline and related risks in patients with chronic kidney disease. This medication is effective in blood sugar control, heart failure management, and kidney protection.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other blood glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine is not recommended for improving glycemic control. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used in patients who are allergic to the active ingredient or excipients, in patients with type 1 diabetes, diabetic ketoacidosis patients, patients with lactose intolerance, or patients undergoing dialysis. Caution is required when used in patients with reduced fluid volume or impaired kidney function due to the risk of low blood pressure or kidney damage. This medication may cause side effects such as genital infections, urinary tract infections, hypoglycemia, dehydration, dizziness, constipation, dry mouth, back pain, etc. Especially, genital infections and urinary tract infections may occur more frequently in women and patients with a history of previous infections, hence prompt treatment is required when symptoms arise. In severe cases, serious infections such as perineal necrosis may occur, so immediate medical attention should be sought if pain or swelling occurs around the perineum. Additionally, this medication can cause serious metabolic disturbances known as ketoacidosis, so immediate examination should be undertaken if symptoms like nausea, vomiting, abdominal pain, or difficulty breathing develop. Elderly patients or those taking diuretics face a higher risk of decreased fluid volume and hypotension, requiring closer monitoring. Women who are pregnant or breastfeeding should avoid using this medication, and discontinuation should occur if pregnancy is confirmed. This medication may increase the risk of hypoglycemia when used with insulin or sulfonylureas, requiring possible dosage adjustments of those drugs. In case of overdose, there is no specific antidote, so appropriate treatment should be administered according to symptoms, and rapid consultation with medical personnel is important. During the use of this medication, caution should be exercised for symptoms of hypoglycemia when driving or operating machinery. Finally, the safety and efficacy of this medication in children have not been established, so it should not be used, and it should be kept out of the reach of children.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, decreased renal creatinine clearance at the beginning of treatment, dyslipidemia, increased serum creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, weakness, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, choledocholithiasis, cholangitis, alcoholic cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, sensory disturbances, cerebral infarction, nerve compression, sensory reduction, headache, nasopharyngitis, upper respiratory tract infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like syndrome, chest pain, fatigue, hunger, vaginal discharge, menstrual irregularities, itching, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best stored at room temperature between 1 to 30 degrees Celsius. Caution should be taken as storing the medication in extremely hot or cold places can diminish its effectiveness.

Appearance and packaging

Appearance

Yellow, biconvex, rhomboid film-coated tablets

Package unit

28 tablets/box [14 tablets/Alu-Alu*2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.